₹960.25
−0.40%NSE close, 16 Nov 2026
−14.81%
Jubilant Pharmova is a small cap company in the Healthcare sector, listed on NSE under the symbol JUBLPHARMA. At ₹960.25 a share, the market values the whole company at ₹15,295 crore.
In FY26, it reported sales of ₹8,280 crore and a net profit of ₹399 crore, an operating margin of 15.2%. Over the last three years, sales grew 11.0% a year and net profit fell 1.3% a year.
The market values the company at 58.2 times its profit over the last twelve months and 2.14 times its book value; its return on equity is 3.7% and its borrowings are 0.54 times its equity.
Promoters hold 47.68% of the shares, and have pledged 6.6% of their holding. Foreign institutions hold 15.38%, and domestic institutions, mutual funds among them, 13.02%.
Over the past year the share price has fallen 17.3%, and it is 17.4% below its 52-week high.
Companies of a similar size in the same sector include Syngene International, Cohance Lifesciences, Pfizer and Poly Medicure.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Jubilant Pharmova | ₹960.25 | ₹15,295 cr | 58.2 | 3.7% | +20.50% | −17.28% |
| Syngene International | ₹441.20 | ₹17,810 cr | 95.7 | 3.8% | −8.60% | −28.91% |
| Cohance Lifesciences | ₹457.60 | ₹17,508 cr | 369.6 | 1.2% | −14.20% | −36.78% |
| Pfizer | ₹3,818.30 | ₹17,468 cr | 20.3 | 19.6% | +13.20% | −24.65% |
| Poly Medicure | ₹1,684.30 | ₹17,072 cr | 53.6 | 9.8% |
Link of Recording
Press Release on financial Results
The financial results for the period ended September 30, 2026.
Jubilant Therapeutics Announces Oral Presentation of Preliminary Phase 1 Clinical Data for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting
Allotment of 80000 securities pursuant to Non Convertible Securities at its meeting held on November 05, 2026
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 | 2,370 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 1,459 | 1,487 | 1,480 | 1,463 | 1,534 | 1,583 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 | 2,130 |
| Operating profit | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 290 | 339 | 248 | 241 |
| Operating margin | 13.0% | 15.4% | 14.5% | 16.5% | 15.8% | 17.9% | 15.2% | 17.4% | 13.6% | 14.8% | 11.1% | 10.1% |
| Other income | 35.8 | 14.4 | 14.0 | 21.7 | 9.2 | 11.9 | 12.0 | 9.8 | 20.5 | 23.7 | 19.9 | 14.4 |
| Interest | 71.3 | 73.0 | 71.0 | 61.0 | 55.6 | 52.7 | 49.0 | 50.2 | 56.1 | 56.5 | 54.2 | 58.4 |
| Depreciation | 94.6 | 101 | 90.7 | 91.4 | 91.3 | 95.2 | 98.1 | 105 | 121 | 117 | 127 | 135 |
| Profit before tax | 87.9 | −57.1 | 500 | 145 | 131 | 206 | 155 | 190 | 93.5 | 176 | 86.4 | 61.7 |
| Tax | 34.6 | 8.1 | 17.9 | 41.9 | 29.8 | 54.7 | 51.9 | 70.4 | 37.6 | 56.7 | 30.0 | 30.7 |
| Net profit | 66.8 | −58.6 | 482 | 103 | 101 | 154 | 103 | 120 | 55.9 | 119 | 56.5 | 31.2 |
| EPS (₹) | 4.22 | -3.69 | 30.44 | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 | 3.57 | 1.97 |
₹ crore, financial years to March.
| Line | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Sales | 9,154 | 6,099 | 6,059 | 6,703 | 7,235 | 8,280 |
| Expenses | 7,207 | 4,702 | 4,974 | 5,802 | 6,061 | 7,020 |
| Operating profit | 1,947 | 1,396 | 1,085 | 901 | 1,174 | 1,260 |
| Operating margin | 21.3% | 22.9% | 17.9% | 13.4% | 16.2% | 15.2% |
| Other income | 47.4 | 17.6 | 82.3 | 68.7 | 56.8 | 66.0 |
| Interest | 287 | 184 | 145 | 272 | 240 | 212 |
| Depreciation | 462 | 349 | 382 | 382 | 369 | 440 |
| Profit before tax | 1,211 | 860 | 640 | 146 | 981 | 614 |
| Tax | 312 | 297 | 217 | 97.8 | 144 | 217 |
| Net profit | 898 | 836 | 414 | 77.1 | 839 | 399 |
| EPS (₹) | 56.39 | 52.48 | 26.00 | 4.87 | 52.99 | 25.15 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 5,399 | 5,434 | 6,255 | 7,093 | 7,154 |
| Borrowings | 3,410 | 3,414 | 2,437 | 3,220 | 3,892 |
| Total liabilities | 5,765 | 6,127 | 6,518 | 8,427 | 9,508 |
| Fixed assets | 2,298 | 2,158 | 2,132 | 3,510 | 3,550 |
| Investments | 32.8 | 34.4 | 36.0 | 60.6 | 62.3 |
| Cash and equivalents | 1,014 | 956 | 1,088 | 1,267 | 1,220 |
| Total assets | 11,157 | 11,549 | 12,756 | 15,523 | 16,665 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 838 | 1,072 | 1,227 | 380 |
| From investing | −380 | 488 | −1,260 | −797 |
| From financing | −32.6 | −1,453 | 94.9 | 371 |
| Spent on fixed assets | −600 | −1,116 | −1,449 | −867 |
| Free cash flow | 238 | −43.5 | −222 | −487 |
Margins, returns, debt, tax and cash.
| Line | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Net margin | 9.8% | 13.7% | 6.8% | 1.2% | 11.6% | 4.8% |
| Operating margin | 21.3% | 22.9% | 17.9% | 13.4% | 16.2% | 15.2% |
| Return on equity | – | – | – | 1.4% | 13.4% | 5.6% |
| Return on capital employed | – | – | – | 4.7% | 14.1% | 8.0% |
| Return on assets | – | – | – | 0.7% | 6.6% | 2.6% |
| Debt to equity | – | – | – | 0.63 | 0.39 | 0.45 |
| Interest coverage | 5.20 | 5.70 | 5.40 | 1.50 | 5.10 | 3.90 |
| Debt to assets | – | – | – | 0.30 | 0.19 | 0.21 |
| Current ratio | – | – | – | 1.92 | 1.62 | 1.62 |
| Quick ratio | – | – | – | 1.24 | 1.10 | 1.13 |
| Cash ratio | – | – | – | 0.51 | 0.50 | 0.50 |
| Asset turnover | – | – | – | 0.58 | 0.57 | 0.53 |
| Fixed asset turnover | – | – | – | 3.11 | 3.39 | 2.36 |
| Inventory turnover | – | – | – | 1.70 | 2.10 | 2.10 |
| Receivables turnover | – | – | – | 7.30 | 8.10 | 7.70 |
| Gross margin | – | – | – | 68.1% | 68.0% | 68.1% |
| Cash from operations to profit | – | – | 202.0% | – | 128.0% | 308.0% |
| Effective tax rate | 25.8% | 34.6% | 34.0% | 66.8% | 14.7% | 35.3% |
| +30.80% |
| −11.21% |
| Natco Pharma | ₹828.65 | ₹16,255 cr | 19.6 | 8.5% | −29.00% | +3.52% |
|---|
| Indegene | ₹662.40 | ₹15,962 cr | 38.8 | 12.2% | +39.60% | +24.95% |
|---|
| Vijaya Diagnostic Centre | ₹1,487.50 | ₹15,321 cr | 75.2 | 19.3% | +26.70% | +46.11% |
|---|
| Marksans Pharma | ₹309.20 | ₹14,016 cr | 25.0 | 16.8% | +30.50% | +67.52% |
|---|
Schedule of meet
Notice of Postal Ballot
Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis
Outcome of Board Meeting held on October 12, 2026 for the Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis
General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST